EBV CTL epitopes

US6703024B2 · kind B2 · utility

Assignees

• The Council of the Queensland Institute of Medical Research · AU
• CSL LIMITED · AU
• BIOTECH AUSTRALIA PTY. LTD. · AU
• THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH · AU
• The University of Melbourne · AU
• COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION · AU

Inventors

• Rajiv Khanna · Bowen Bridge, AU
• Beverley Mavis Kerr · Cleveland, AU
• Ihor Stephan Misko · Brisbane, AU
• Denis James Moss · Brisbane, AU
• Scott Burrows · Bald Hills, AU

Key dates

• Filing date: Aug 1, 2001
• Grant date: Mar 9, 2004
• Expiry date: Sep 30, 2021

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides cytotoxic Epstein-Barr virus T-cell epitopes. These epitopes are QVKWRMTTL, VFSDGRVAC, VPAPAGPIV, TYSAGIVQI, LLDFVRFMGV, QNGALAINTF, VSSDGRVAC, VSSEGRVAC, VSSDGRVPC, VSSDGLVAC, VSSDGQVAC, VSSDGRVVC, VPAPPVGPIV, VEITPYEPTG, VEITPYEPTW, VELTPYKPTW, RRIYDLIKL, RKIYDLIEL and PYLFWLAGI. The present invention further provides vaccines including one or more of these epitopes, optionally with additional epitopes.